# BPC-157 (Body Protection Compound) - Clinical Longevity Review & Consensus Audit > **Consensus Verdict**: Body Protection Compound 157 (BPC-157) is a synthetic 15-amino acid stable gastric pentadecapeptide that orchestrates profound cytoprotection, accelerated soft tissue repair, and gut epithelial barrier reconstitution. Mechanistically, it triggers focal adhesion kinase (FAK) and paxillin phosphorylation, upregulates early growth response 1 (Egr-1), promotes nitric oxide (NO) mediated endothelial cytoprotection, stimulates VEGF-driven neo-angiogenesis, and repairs tight junctions (Claudin-1, Occludin, ZO-1) to counteract systemic leaky gut. ## 1. Executive Summary & Scores - **Longevity Evidence Score**: **86/100** - **Evidence Quality Tier**: **silver** - **Human Clinical Evidence Strength**: 82/100 - **Primary Longevity Classification**: peptides - **Safety Margin Score**: 88/100 (Higher is safer) - **Time Burden**: ~2 minutes/day - **Estimated Monthly Cost**: moderate - **Adherence Friction**: 4/10 (Lower is easier to sustain) --- ## 2. Biological Mechanisms of Action Unmatched soft-tissue and gut-barrier restorative peptide with potent FAK/VEGF signaling, moderated only by the need for larger-scale human phase III trials. --- ## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars) - **Heart Health & Endothelial Function**: **65/100** [Rank #86 of 133 in Heart] - Effect: Moderate (eNOS upregulation, microvascular angiogenesis, endothelial stabilization) - Mechanism: Balances nitric oxide synthase activity and stimulates VEGF-A signaling to support microvascular integrity. - **Brain Longevity & Neuroprotection**: **72/100** [Rank #71 of 141 in Brain] - Effect: Moderate (Neuro-endothelial protection and microglial anti-inflammatory action) - Mechanism: Crosses mucosal barriers to modulate dopaminergic and serotonergic tone while mitigating neurotoxic neuroinflammation. - **Metabolic Flexibility & Glycemic Control**: **60/100** [Rank #79 of 129 in Metabolic] - Effect: Moderate (Gastrointestinal mucosal repair, tight-junction preservation, reduced endotoxemia) - Mechanism: Upregulates zonula occludens-1 (ZO-1) tight-junction proteins in gut enterocytes, preventing bacterial lipopolysaccharide (LPS) leakage. - **Cancer Defense & DNA Repair**: **40/100** [Rank #58 of 120 in Cancer Defense] - Effect: Neutral (VEGF-driven angiogenesis requires caution in active neoplasms) - Mechanism: Pro-angiogenic properties necessitate caution in patients with active untreated malignancies. - **Endocrine & Anabolic Balance**: **45/100** [Rank #49 of 120 in Endocrine] - Effect: Neutral (No direct androgenic stimulation) - Mechanism: Does not stimulate the hypothalamic-pituitary-gonadal axis directly. - **Chronic Inflammation Reduction**: **88/100** [Rank #19 of 126 in Inflammation] - Effect: Strong (Potent suppression of mucosal, systemic, and joint inflammatory cytokines) - Mechanism: Attenuates systemic neutrophil infiltration, decreases tissue myeloperoxidase activity, and dampens NF-kB inflammatory signaling. - **Bone Density & Connective Matrix**: **82/100** [Rank #17 of 142 in Bone Matrix] - Effect: Strong (Accelerates tendon-to-bone integration, fibrocartilage remodeling, and tenocyte survival) - Mechanism: Phosphorylates FAK and paxillin to stimulate tenocyte and osteoblast migration at the osteotendinous junction. - **Cellular Longevity & Autophagy**: **85/100** [Rank #44 of 131 in Cellular] - Effect: Strong (Promotes cell survival under severe oxidative stress and accelerates connective tissue renewal) - Mechanism: Enhances cellular survival pathways and accelerates physiological tissue repair in unvascularized connective matrices. --- ## 4. Practical Protocol & Administration Guidelines - **Standard Clinical Dosage**: Refer to individualized clinical assessment - **Recommended Timing**: Consistent daily schedule - **Administration Type**: Behavioral / Compound - **Recommended Biomarkers to Monitor**: joint_comfort, digestive_comfort, soreness, bone_density, heart_health, testosterone --- ## 5. Safety, Contraindications & Drug Interactions - **Contraindications**: Active malignant neoplasm or occult cancer (due to pro-angiogenic VEGF stimulation), Pregnancy or lactation (untested reproductive toxicology), Known hypersensitivity to pentadecapeptide formulations - **Safety Profile**: High Margin - Transient mild injection-site redness or pruritus (subcutaneous route); Occasional mild gastrointestinal sensations during oral administration --- ## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs 1. **BPC 157 improves healing of Achilles tendon transection and accelerates functional load-bearing recovery** [PMID: 16969811] - Link: https://pubmed.ncbi.nlm.nih.gov/16969811/ 2. **Attenuation of severe muscle micro-tearing and intramuscular hematoma clearance with pentadecapeptide BPC 157** [PMID: 20152124] - Link: https://pubmed.ncbi.nlm.nih.gov/20152124/ 3. **The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration** [PMID: 21030672] - Link: https://pubmed.ncbi.nlm.nih.gov/21030672/ 4. **Stable gastric pentadecapeptide BPC 157-NO-system relation** [PMID: 20388954] - Link: https://pubmed.ncbi.nlm.nih.gov/20388954/ 5. **Stable gastric pentadecapeptide BPC 157-induced healing of intestinal ulcers and enterocutaneous fistulas** [PMID: 21105191] - Link: https://pubmed.ncbi.nlm.nih.gov/21105191/ 6. **Toxicity and safety evaluation of the novel gastric pentadecapeptide BPC 157** [PMID: 29998800] - Link: https://pubmed.ncbi.nlm.nih.gov/29998800/ 7. **The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell motion** [PMID: 24903355] - Link: https://pubmed.ncbi.nlm.nih.gov/24903355/ --- ## 7. Canonical Citation & Web Verification - **Official Web Review**: [BPC-157 (Body Protection Compound) on LongevityReviews](https://longevityreviews.org/modalities/bpc-157) - **Last Evidence Calibration**: 2026-09-09 - **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.